Predicted protein targets (top 16)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | ALDH1A1 | P00352 | 2/20 | 1.00 |
| ▸ | CYP1A2 | P05177 | 2/20 | 0.80 |
| ▸ | CYP3A4 | P08684 | 2/20 | 0.80 |
| ▸ | CYP2C19 | P33261 | 2/20 | 0.80 |
| ▸ | CYP2C9 | P11712 | 2/20 | 0.80 |
| ▸ | HTT | P42858 | 1/20 | 0.60 |
| ▸ | PDE10A | Q9Y233 | 1/20 | 0.51 |
| ▸ | KMT2A | Q03164 | 3/20 | 0.50 |
| ▸ | MEN1 | O00255 | 2/20 | 0.50 |
| ▸ | MAPT | P10636 | 2/20 | 0.50 |
| ▸ | NOTUM | Q6P988 | 2/20 | 0.50 |
| ▸ | LMNA | P02545 | 1/20 | 0.47 |
| ▸ | NPSR1 | Q6W5P4 | 1/20 | 0.47 |
| ▸ | POLB | P06746 | 2/20 | 0.46 |
| ▸ | CTSK | P43235 | 1/20 | 0.45 |
| ▸ | MAPK1 | P28482 | 1/20 | 0.44 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL519083 | 0.90 | ALDH1A1 (0.82) | ALDH1A1CYP1A2CYP3A4CYP2C19CYP2C9 | |
| SCHEMBL518941 | 0.89 | CYP1A2 (1.00) | ALDH1A1CYP1A2CYP3A4CYP2C19CYP2C9 | |
| SCHEMBL519277 | 0.87 | ALDH1A1 (0.77) | ALDH1A1CYP1A2CYP3A4CYP2C19CYP2C9 | |
| SCHEMBL519551 | 0.85 | ALDH1A1 (0.73) | ALDH1A1CYP1A2CYP3A4CYP2C19CYP2C9 | |
| SCHEMBL519055 | 0.84 | ALDH1A1 (0.72) | ALDH1A1CYP1A2CYP3A4CYP2C19CYP2C9 | |
| SCHEMBL519038 | 0.83 | ALDH1A1 (0.71) | ALDH1A1CYP1A2CYP3A4CYP2C19CYP2C9 | |
| SCHEMBL519090 | 0.83 | PDE10A (0.74) | ALDH1A1CYP1A2CYP3A4CYP2C19CYP2C9 | |
| SCHEMBL2477179 | 0.83 | ALDH1A1 (0.71) | ALDH1A1CYP1A2CYP3A4CYP2C19CYP2C9 | |
| Benzene SCHEMBL3434254 | 0.83 | ALDH1A1 (0.71) | ALDH1A1CYP1A2CYP3A4CYP2C19CYP2C9 | |
| SCHEMBL519415 | 0.83 | ALDH1A1 (0.70) | ALDH1A1CYP1A2CYP3A4CYP2C19CYP2C9 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 23 patents — showing the first 20. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-20170114044-A1 | PYRIDAZINONE COMPOUNDS AS PHOSPHODIESTERASE INHIBITORS AND METHODS OF TREATING DISORDERS | TAKEDA PHARMACEUTICALS CO (JP) | 2017-04-27 | — | — | US | claimed |
| EP-3006031-A1 | PYRIDAZINONE COMPOUNDS | Takeda Pharmaceutical Company Limited (JP) | 2016-04-13 | — | — | EP | claimed |
| US-20120277204-A1 | PYRIDAZINONE COMPOUNDS | TANIGUCHI TAKAHIKO (GB) | 2012-11-01 | — | — | US | claimed |
| US-20120028951-A1 | PYRIDAZINONE COMPOUNDS | TAKEDA PHARMACEUTICAL COMPANY LIMITED (JP) | 2012-02-02 | — | — | US | claimed |
| EP-2393360-A1 | PYRIDAZINONE COMPOUNDS | Takeda Pharmaceutical Company Limited (JP) | 2011-12-14 | — | — | EP | claimed |
| WO-2010090737-A1 | PYRIDAZINONE COMPOUNDS | TAKEDA PHARMACEUTICAL COMPANY LIMITED (JP) | 2010-08-12 | — | — | WO | claimed |
| US-20100197651-A1 | Pyridazinone compounds | TAKEDA PHARMACEUTICAL COMPANY LIMITED (JP) | 2010-08-05 | — | — | US | claimed |
| US-20170114044-A1 | PYRIDAZINONE COMPOUNDS AS PHOSPHODIESTERASE INHIBITORS AND METHODS OF TREATING DISORDERS | TAKEDA PHARMACEUTICALS CO (JP) | 2017-04-27 | — | — | US | disclosed |
| US-9550756-B2 | Pyridazinone compounds as phosphodiesterase inhibitors and methods of treating disorders | TAKEDA PHARMACEUTICAL COMPANY LIMITED (JP) | 2017-01-24 | — | — | US | disclosed |
| EP-3006031-A1 | PYRIDAZINONE COMPOUNDS | Takeda Pharmaceutical Company Limited (JP) | 2016-04-13 | — | — | EP | disclosed |
| US-20150099757-A1 | PYRIDAZINONE COMPOUNDS AS PHOSPHODIESTERASE INHIBITORS AND METHODS OF TREATING DISORDERS | TAKEDA PHARMACEUTICAL (JP) | 2015-04-09 | — | — | US | disclosed |
| US-8916566-B2 | Pyridazinone compounds as phosphodiesterase inhibitors and methods of treating disorders | TAKEDA PHARMACEUTICAL COMPANY LIMITED (JP) | 2014-12-23 | — | — | US | disclosed |
| US-8778944-B2 | Pyridazinone compounds | TAKEDA PHARMACEUTICAL COMPANY LIMITED (JP) | 2014-07-15 | — | — | US | disclosed |
| US-20120277430-A1 | PYRIDAZINONE COMPOUNDS | TANIGUCHI TAKAHIKO (GB) | 2012-11-01 | — | — | US | disclosed |
| US-20120277431-A1 | PYRIDAZINONE COMPOUNDS | TANIGUCHI TAKAHIKO (GB) | 2012-11-01 | — | — | US | disclosed |
| US-20120277204-A1 | PYRIDAZINONE COMPOUNDS | TANIGUCHI TAKAHIKO (GB) | 2012-11-01 | — | — | US | disclosed |
| US-20120028951-A1 | PYRIDAZINONE COMPOUNDS | TAKEDA PHARMACEUTICAL COMPANY LIMITED (JP) | 2012-02-02 | — | — | US | disclosed |
| EP-2393360-A1 | PYRIDAZINONE COMPOUNDS | Takeda Pharmaceutical Company Limited (JP) | 2011-12-14 | — | — | EP | disclosed |
| WO-2010090737-A1 | PYRIDAZINONE COMPOUNDS | TAKEDA PHARMACEUTICAL COMPANY LIMITED (JP) | 2010-08-12 | — | — | WO | disclosed |
| US-20100197651-A1 | Pyridazinone compounds | TAKEDA PHARMACEUTICAL COMPANY LIMITED (JP) | 2010-08-05 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (7 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20120277431-A1 | PYRIDAZINONE COMPOUNDS | PDE3A, PDE5A, PDE3B | ALDH1A1 350/4885CYP1A2 116/4885CYP3A4 341/4885 |
| US-20120277430-A1 | PYRIDAZINONE COMPOUNDS | PDE3A, PDE5A, PDE3B | ALDH1A1 350/4885CYP1A2 116/4885CYP3A4 341/4885 |
| US-20150099757-A1 | PYRIDAZINONE COMPOUNDS AS PHOSPHODIESTERASE INHIBITORS AND METHODS OF TREATING DISORDERS | PDE3A, PDE5A, PDE3B | ALDH1A1 331/4885CYP1A2 116/4885CYP3A4 466/4885 |
| US-20170114044-A1 | PYRIDAZINONE COMPOUNDS AS PHOSPHODIESTERASE INHIBITORS AND METHODS OF TREATING DISORDERS | PDE3A, PDE5A, PDE3B | ALDH1A1 343/4885CYP1A2 120/4885CYP3A4 432/4885 |
| US-20120277204-A1 | PYRIDAZINONE COMPOUNDS | PDE3A, PDE5A, PDE3B | ALDH1A1 350/4885CYP1A2 116/4885CYP3A4 341/4885 |
| US-20120028951-A1 | PYRIDAZINONE COMPOUNDS | PDE3A, PDE5A, PDE3B | ALDH1A1 350/4885CYP1A2 116/4885CYP3A4 341/4885 |
| US-20100197651-A1 | Pyridazinone compounds | PDE3A, PDE5A, PDE3B | ALDH1A1 334/4885CYP1A2 109/4885CYP3A4 320/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.